SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

Super-universal CD7 CART (supCD7 CART) Cell Injection in the Treatment of Relapsed or Refractory CD7 Positive Hematologic Malignancies: a Prospective, Single-arm, Single-center Clinical Study.

The aim of this study was to evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies. In this single-arm, open-label, single-center, Phase Ⅰ+Ⅱ clinical trial, two cohorts were set up: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory T-ALL/LBL cohort. Each cohort was planned to enroll 4-12 patients. SupCD7 CART cells will be administered intravenously to explore the MTD of each cohort using a 3+3 dose escalation and rapid titration design.

Study Overview

• Status: Recruiting
• Conditions: Acute Myeloid Leukemia (AML); T Lymphoblastic Leukemia/Lymphoma
• Intervention / Treatment: Biological: supCD7 CART cells

Detailed Description

This study will use super-universal CD7 CART cells to treat CD7-positive relapsed or refractory hematological malignancies, especially AML and T-ALL/LBL patients. Two cohorts were established: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory T-ALL/LBL cohort. A 3+3 dose escalation and rapid titration design was used to explore the MTD for each cohort. 3+3 dose escalation CART cells dose groups were (1) 0.5×10^6 CART cells/kg; (2)1×10^6 CART cells/kg;(3) 3×10^6 CART cells/kg. A minimum of 4 and a maximum of 12 patients are expected to be enrolled. Fludarabine and cyclophosphamide-based preconditioning should be performed within 1 week prior to supCD7 CART cells infusion. supCD7 CART cells can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met. To evaluate the safety and efficacy of supCD7 CART cells in the treatment of patients with relapsed/refractory CD7-positive hematologic malignancies.

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Jianxiang Wang; Phone Number: +862223909120; Email: wangjx@ihcams.ac

Study Locations

• China
  • Tianjin Municipality
    • Tianjin, Tianjin Municipality, China
      • Recruiting
      • Institute of Hematology & Blood Diseases Hospital
      • Contact: Jianxiang Wang; Phone Number: 022-23909120; Email: wangjx@ihcams.ac.cn
      • Principal Investigator: Ying Wang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥18 and <70 years, regardless of gender;
• T-ALL/LBL was diagnosed according to the criteria of NCCN Clinical Practice Guidelines for Acute Lymphocytic Leukemia (2020.v1) and T-cell Lymphoma Clinical Practice Guidelines (2020.v1);
• Patients diagnosed with AML with reference to the Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2018 Edition) issued by the Health Commission;
• Cytology confirmed that the tumor cells were CD7 positive.
• Number of blasts in bone marrow ≥5% at screening (bone marrow morphology);
• Complies with the diagnosis of relapsed/refractory AML, including any of the following conditions according to China Guidelines for Diagnosis and Treatment of Relapsed/Refractory Acute Myeloid Leukemia (2021 Edition): a. Primary refractory patients who did not achieve CR after two cycles of standard induction chemotherapy; b. CR after consolidation chemotherapy, relapse within 12 months; c. Relapse 12 months after remission but ineffective after conventional chemotherapy; d. 2 or more relapses; e. Relapse after hematopoietic stem cell transplantation.
• Meet the diagnosis of relapsed/refractory T-ALL/LBL, including any of the following: a. Primary refractory patients who have not achieved complete response after two cycles of standard chemotherapy, or patients who have not achieved complete response after multi-line rescue chemotherapy; b. Relapse within <12 months after complete remission or ≥12 months after complete remission and fail to achieve complete remission induced by 1 or more cycles of standard treatment; c. Relapse after hematopoietic stem cell transplantation or relapse after CAR-T therapy at the same target;
• Complies with diagnosis of other relapsed/refractory CD7 positive hematologic malignancies
• Creatine clearance >60ml/min (Cockcroft and Gault formula); serum total bilirubin ≤3 times the upper limit of normal, serum ALT and AST ≤5 times the upper limit of normal range for patients without liver invasion;
• showing left ventricular ejection fraction (LVEF) ≥50%;
• Pulse oxygen saturation ≥92%;
• The estimated survival time is more than 3 months;
• score 0-2;
• Subjects or their legal guardians voluntarily participate in this trial and sign the informed consent form.

Exclusion Criteria:

Subjects who met any of the following criteria were excluded from the study：

• acute promyelocytic leukemia (APL);
• Presence of a genetic syndrome such as Fanconi's anemia, Kostmann's syndrome, Shwachman syndrome or any other known syndrome of bone marrow failure;
• Patients with uncontrolled active central nervous system leukemia (CNSL), i.e. cerebrospinal fluid grades CNS 2 and CNS 3;
• Patients who have received anti-tumor therapy before infusion should be excluded if any of the following conditions are met: a. Systemic chemotherapy (except for pretreatment) within 1 week; b. For those who have received monoclonal antibody therapy, the last time of monoclonal antibody infusion is less than 5 half-lives or 4 weeks (whichever is shorter) at screening; c. Received donor lymphocyte infusion (DLI) within 6 weeks;
• Presence of uncontrolled, serious, active infection at screening;
• Patients with a history of serious heart disease, including: severe cardiac insufficiency (subjects with cardiac insufficiency of Class III or IV according to the New York Heart Association (NYHA) cardiac function classification standard), myocardial infarction within 12 months or cardiac angioplasty or stenting, unstable angina pectoris, ECG indicating significant QT interval prolongation (>480ms) or serious arrhythmia judged by the investigator;
• Previous craniocerebral trauma, disturbance of consciousness, epilepsy, cerebral ischemia, cerebral vascular hemorrhagic disease and other medical history, and within six months of the need for drug treatment;
• Patients with hepatitis B surface antigen (HBsAg) greater than 10E6 IU/mL, hepatitis C virus (HCV) antibody positive, human immunodeficiency virus (HIV) antibody positive, syphilis antibody test positive, EBER positive or EBV copy number greater than the upper limit of normal at screening;
• Patients who must use steroid hormones during CAR-T infusion (except for local or inhaled steroid hormones); subjects who are receiving systemic steroid therapy before screening and need long-term systemic steroid therapy during treatment according to the investigator's judgment (except for inhaled or local use);
• Subjects with autoimmune diseases requiring treatment, immunodeficient subjects, or subjects requiring immunosuppressive treatment;
• Patients with acute graft-versus-host disease (GvHD) or moderate-to-severe chronic GvHD within 4 weeks prior to screening;
• Patients with a history of allergy to any component of cell products;
• Pregnant, lactating females, and subjects (male or female) of childbearing potential who are unable to use effective contraception within 1 year after cell infusion; male subjects who plan to become pregnant within 1 year after cell infusion; female subjects or partners who plan to become pregnant within 1 year after cell infusion;
• Any condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the results of the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: The efficacy of supCD7 CART cell therapy; This study will employ supCD7 CART cells to treat CD7-positive relapsed or refractory hematologic malignancies, particularly in patients with AML and T-ALL/LBL, with the aim of improving the re-remission rate in AML and T-ALL/LBL and providing a new therapeutic option to enhance their long-term survival.

Biological: supCD7 CART cells; Subjects screened to meet the requirements for supCD7 CART cells use will enter clinical trials. Subjects were assessed at baseline. Fludarabine and cyclophosphamide based preconditioning should be performed within 1 week prior to supCD7 CART cells infusion: fludarabine (Flu) 30mg/m2 ×3 days; cyclophosphamide (CTX) 500mg/m2 ×3 days. The investigator can adjust the pretreatment regimen appropriately according to the condition of the subject, such as increasing the dose of CTX to 600mg/m2 ×3 days, increasing the application of cytarabine and VP-16. Infusion of supCD7 CART cells must be performed 24 hours after completion of chemotherapy preconditioning. supCD7 CART cells can be infused at D-1 if the requirement of 24 hours after completion of preconditioning is met.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Response Rate (ORR)	The proportion of patients achieving CR (complete remission) or CRi (complete remission with incomplete hematologic recovery) for T-ALL/LBL.; The proportion of patients achieving CR, CRi, or PR (partial remission) for T-ALL/LBL.; The proportion of patients achieving CRc [composite complete remission, including CR/CRh (complete remission with partial hematologic recovery)] or CRi for AML.	Efficacy will be evaluated at Weeks 4, 8, and 12 following supCD7 CART cell infusion.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total MRD-negative response rate (MRD-ORR) in bone marrow after supCD7 CART cell infusion	The proportion of patients achieving CR/CRi (T-ALL/LBL) or CRc (AML) who are MRD-negative in the bone marrow.	3 months after supCD7 CART cells infusion
Duration of remission (DOR)	The time from first achieving CR/CRi + PR (T-ALL/LBL) or CRc + PR (AML) after supCD7 CAR-T infusion to disease relapse or death due to leukemia.	Participants will be followed for the duration of the treatment, an expected average of 24 months
Event-free survival (EFS)	The time from supCD7 CAR-T infusion to the earliest occurrence of any of the following events: death from any cause after remission, relapse, no response to treatment, or treatment discontinuation due to leukemia- and/or treatment-related death, adverse events, or initiation of new anti-tumor therapy (excluding bridging transplantation).	Participants will be followed for the duration of the treatment, an expected average of 24 months.
Leukemia-free survival (LFS)	The time from first achieving CR/CRi (ALL/LBL) or CRc (AML) to relapse or death.	Participants will be followed for the duration of the treatment, an expected average of 24 months.
Proportion of patients undergoing hematopoietic stem cell transplantation (HSCT) in remission	The proportion of patients who receive HSCT among those achieving remission after infusion.	Participants will be followed for the duration of the treatment, an expected average of 24 months.

Collaborators and Investigators

• Sponsor: Institute of Hematology & Blood Diseases Hospital, China
• Investigators: Principal Investigator: Jianxiang Wang, Institute of Hematology & Blood Diseases Hospital, China

Study record dates

Study Major Dates

• Study Start (Actual): June 28, 2025
• Primary Completion (Estimated): June 28, 2028
• Study Completion (Estimated): June 28, 2030

Study Registration Dates

• First Submitted: August 26, 2025
• First Submitted That Met QC Criteria: August 26, 2025
• First Posted (Estimated): September 3, 2025

Study Record Updates

• Last Update Posted (Actual): December 15, 2025
• Last Update Submitted That Met QC Criteria: December 11, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Acute myeloid leukemia (AML); Prospective study; Single-arm Clinical Study; T lymphoblastic leukemia/lymphoma (T-ALL/LBL); Super-universal CD7 CAR-T (supCD7 CAR-T)
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Leukemia, Myeloid; Leukemia; Hemic and Lymphatic Diseases; Leukemia, Myeloid, Acute; Lymphoma
• Other Study ID Numbers: IIT2025074

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No